LT4 logo

Liquidia MUN:LT4 Stock Report

Last Price

€10.49

Market Cap

€900.4m

7D

-5.9%

1Y

1.3%

Updated

22 Dec, 2024

Data

Company Financials +

LT4 Stock Overview

A biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. More details

LT4 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Liquidia Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Liquidia
Historical stock prices
Current Share PriceUS$10.49
52 Week HighUS$15.62
52 Week LowUS$8.51
Beta0.22
1 Month Change3.55%
3 Month Changen/a
1 Year Change1.25%
3 Year Changen/a
5 Year Changen/a
Change since IPO-14.44%

Recent News & Updates

Recent updates

Shareholder Returns

LT4DE PharmaceuticalsDE Market
7D-5.9%-2.2%-2.0%
1Y1.3%-15.6%6.9%

Return vs Industry: LT4 exceeded the German Pharmaceuticals industry which returned -15.6% over the past year.

Return vs Market: LT4 underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is LT4's price volatile compared to industry and market?
LT4 volatility
LT4 Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: LT4's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine LT4's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004145Roger Jeffswww.liquidia.com

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion.

Liquidia Corporation Fundamentals Summary

How do Liquidia's earnings and revenue compare to its market cap?
LT4 fundamental statistics
Market cap€900.38m
Earnings (TTM)-€114.50m
Revenue (TTM)€14.96m

60.2x

P/S Ratio

-7.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LT4 income statement (TTM)
RevenueUS$15.61m
Cost of RevenueUS$5.52m
Gross ProfitUS$10.09m
Other ExpensesUS$129.57m
Earnings-US$119.47m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.41
Gross Margin64.65%
Net Profit Margin-765.37%
Debt/Equity Ratio102.4%

How did LT4 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:28
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Liquidia Corporation is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory HarrisonBofA Global Research
Jason Matthew GerberryBofA Global Research
Julian HarrisonBTIG